Emerging Anti-Atherosclerotic Therapies

Area of Science:

• Cardiovascular medicine
• Immunology
• Pharmacology

Background:

• Cardiovascular disease (CAD), driven by atherosclerosis, is a primary cause of mortality globally.
• Atherosclerosis development starts early, influenced by genetic and environmental factors, yet current risk factor identification and therapies remain insufficient.
• Existing treatments fail to prevent a significant portion of clinical events, highlighting the need for novel preventive strategies.

Purpose of the Study:

• To explore emerging therapeutic targets beyond lipid metabolism for anti-atherosclerotic drug development.
• To review the current status and future potential of novel drug candidates targeting inflammation, immunity, and other pathways in atherosclerosis.
• To assess the need for further clinical validation of promising, yet unconfirmed, therapeutic agents.

Main Methods:

• Review of current literature on atherosclerosis pathogenesis and therapeutic targets.
• Analysis of emerging drug classes including cyclodextrins, kinase inhibitors, and immunomodulators.
• Evaluation of preliminary data for agents targeting inflammation (e.g., IL-1β, p38 MAPK) and immune mechanisms.

Main Results:

• Several novel therapeutic targets, focusing on inflammation and immunity, are under investigation.
• Agents such as colchicine, p38 MAPK inhibitors, and anti-IL-1β antibodies show preliminary promise.
• The therapeutic potential of these agents requires confirmation through large-scale clinical trials.

Conclusions:

• Novel therapeutic strategies targeting inflammation and immune responses offer potential for improved prevention of atherosclerosis.
• Further research and robust clinical trials are essential to validate the efficacy and safety of these emerging treatments.
• A paradigm shift towards targeting inflammatory and immune pathways is crucial for advancing CAD prevention and treatment.